东京——7月23日，深陷“红曲风波”的日本小林制药公司召开董事会，宣布现年84岁的董事长小林一雅和现年53岁的社长小林章浩引咎辞职。接任社长职务的是现年59岁的专务董事山根聪。这一变动反映了公司在面对重大健康安全争议时，对领导层责任的深刻反思与自我修正。
### “红曲风波”与危机管理失当
小林制药在今年1月中旬已收到其含红曲成分保健品致人健康受损的报告，但公司却将“锁定问题物质”视为优先事项，延误了问题的公开与产品的召回，直至两个多月后才正式公布相关健康受损问题。这一决策引发了公众的广泛质疑和不满，小林制药的两位最高层因此承担起责任，退出了公司的一线运营。
### 外部调查与责任承认
日本《读卖新闻》报道，由外部律师组成的“事实验证委员会”对小林制药进行了深入调查，并于7月23日公布了调查报告书。报告指出，小林制药在危机管理中的最大问题在于领导层的失职，未能将消费者的安全放在首位，忽视了及时公布健康受损情况和召回问题产品的紧迫性。对此，小林制药正式承认了公司在危机管理上的失误。
### 调查进展与消费者权益保护
截至7月21日，小林制药正在对101名死者与其红曲保健品之间的因果关系进行调查，另有3名死者的用药情况还在确认之中。日本厚生劳动大臣武见敬三表示，调查预计将在8月中旬结束。这一事件凸显了小林制药在产品安全和消费者权益保护方面存在的重大问题，也引发了公众对保健品安全性的广泛关注。
### 山根聪接任与未来展望
山根聪的接任不仅象征着小林制药在管理层上的新面貌，也预示着公司未来在产品安全、危机管理以及消费者权益保护方面将采取更加积极的措施。此次领导层的变动，不仅是为了应对当前的危机，也是为了确保小林制药能够从这次事件中吸取教训，重塑公众信任，恢复公司在市场中的声誉。
### 结语
此次事件不仅对小林制药造成了严重的声誉损失，也引发了行业内的深刻反思。对于消费者而言，它提醒了在选择保健品时需要更加谨慎，同时对于企业而言，则强调了在产品开发和销售过程中，确保消费者安全的重要性。小林制药此次的领导层变动，预示着公司在未来将采取更加负责任的态度，以重建与消费者的信任关系。
英语如下：
### Tokyo — July 23: Japanese Pharmaceutical Giant Kosei Pharmaceutical Sees Top Leadership Resign Over Red曲 Controversy
In a significant move that reflects a deep-seated reflection on corporate responsibility and self-correction, the 84-year-old chairman, Mr. Shigehisa Kosei, and the 53-year-old CEO, Mr. Takahiro Kosei, of Japanese pharmaceutical giant Kosei Pharmaceutical, have resigned from their positions, amidst a storm of controversy surrounding the company’s red曲 product. Mr. Akihiko Yamaguchi, aged 59, has been appointed as the new CEO.
This comes after the company received reports in mid-January this year about its health supplements containing red曲 causing health issues for consumers. Despite this, the company prioritized identifying the problematic substance over addressing the immediate concerns of the public and recalling the product, leading to significant public criticism and dissatisfaction. This led to the resignation of the top executives, who took responsibility for the company’s failure in crisis management.
### Investigation and Admission of Faults
The Yomiuri Shimbun reported that an external legal team, known as the “Truth Verification Committee,” conducted a thorough investigation into Kosei Pharmaceutical and presented its findings on July 23. The report highlighted the company’s leadership’s failure to prioritize consumer safety, and its neglect of the urgency to disclose health issues and recall the problematic product. Kosei Pharmaceutical officially acknowledged its mistakes in handling the crisis.
### Progress in Investigation and Consumer Protection
As of July 21, Kosei Pharmaceutical is investigating the cause of death for 101 deceased individuals and is still confirming the usage history of three more. The Ministry of Health, Labor, and Welfare’s Minister, Katsunobu Kato, stated that the investigation is expected to conclude by mid-August. This incident has raised significant concerns about product safety and consumer protection within Kosei Pharmaceutical, as well as heightened public awareness about the safety of health supplements.
### A New Leadership and Future Prospects
Mr. Yamaguchi’s appointment signifies a new chapter for Kosei Pharmaceutical, not only in its leadership but also in its commitment to product safety, crisis management, and consumer rights protection. This move is not only a response to the current crisis but also a step towards ensuring that Kosei Pharmaceutical can learn from this incident, regain public trust, and restore its reputation in the market.
### Conclusion
The repercussions of this incident have not only caused substantial damage to Kosei Pharmaceutical’s reputation but have also sparked profound reflections within the industry. For consumers, it serves as a reminder to exercise caution when choosing health supplements, while for companies, it underscores the paramount importance of ensuring consumer safety in the development and sale of products. The recent leadership changes at Kosei Pharmaceutical signal the company’s commitment to adopting a more responsible approach to rebuilding trust with its consumers.
【来源】http://www.chinanews.com/gj/2024/07-23/10256114.shtml
Views: 2